Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | R/R myeloma: iberdomide, dex & dara or bortezomib

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, talks on the first results of iberdomide, a potent cereblon E3 ligase modulator, in combination with dexamethasone (dex) and daratumumab (dara) or bortezomib in patients with relapsed/refractory multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Sagar Lonial, MD, has done consultancy work for Takeda, Celgene, BMS, Janssen, GSK, Abbvie, Novartis and Janssen; and has been a member of a board of directors for TG Therapeutics.